Medpage Today on MSN11d
FDA Approves Novel Treatment for UTIsThe FDA approved oral sulopenem etzadroxil and probenecid (Orlynvah) to treat uncomplicated urinary tract infections (uUTIs) ...
The FDA has approved Orlynvah, a new oral treatment for uncomplicated urinary tract infections (UTIs) in women who have limited options for effective antibiotic therapy.
The US Food and Drug Administration (FDA) approved a new oral antibiotic to treat uncomplicated urinary tract infections ...
The US Food and Drug Administration has approved a new oral antibiotic for treatment of uncomplicated urinary tract ...
Despite recent concerns from the FDA about potential off-label use and antimicrobial resistance, Dublin-based Iterum ...
Orlynvah is the first oral penem approved in the U.S. and Iterum Therapeutics’ first FDA-approved product. CEO Corey Fishman ...
The U.S. Food and Drug Administration has approved Iterum Therapeutics' oral antibiotic to treat certain types of bacterial ...
The US Food and Drug Administration (FDA) approved Iterum Therapeutics’ (Nasdaq: ITRM) Orlynvah (sulopenem etzadroxil and ...
ORLYNVAH™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades--Company ...
The "Salivary Gland Infection Market Report Global Forecast by Type, Application, Country and Company Analysis 2024-2032" ...
Not much went right for Spero Therapeutics’ SPR720 in its phase 2a trial. | Not much went right for Spero Therapeutics’ SPR720 in its phase 2a trial. An interim analysis revealed a double blow to the ...
U.S. Food and Drug Administration has approved Iterum Therapeutics' oral antibiotic to treat certain types of bacterial urinary tract infections (UTI) in adult women, the health regulator said Friday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback